Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.51 |
| ▸ | HTR1B | P28222 | 9/20 | 0.48 |
| ▸ | HTR1A | P08908 | 7/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532963 | 0.90 | NCF1 (0.58) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL13945359 | 0.88 | HTR1D (0.51) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL8088915 | 0.88 | HTR1D (0.51) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL4249271 | 0.88 | SMN1; SMN2 (0.49) | HTR1DHTR1BHTR1ANCF1DRD2 | |
| SCHEMBL5529781 | 0.87 | HTR1D (0.51) | HTR1DHTR1BHTR1ANCF1ENPP2 | |
| SCHEMBL13945451 | 0.87 | HTR1D (0.52) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL13945348 | 0.87 | HTR1D (0.61) | HTR1DHTR1BHTR1ANCF1DRD2 | |
| SCHEMBL8235825 | 0.86 | HTR1D (0.49) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL5531637 | 0.85 | HRH3 (0.51) | HTR1DHTR1BHTR1ANCF1DRD2 | |
| SCHEMBL5531716 | 0.85 | HTR1D (0.49) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | HTR1D 483/4885HTR1B 354/4885HTR1A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.